🔎 Trials Near Me

Почетна › Акутна миелоидна леукемија › Орегон › Portland

Клинички испитувања за Акутна миелоидна леукемија во Portland, OR

25 студии за Акутна миелоидна леукемија бараат учесници на локации во и околу Portland (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.

Официјален текст на студијата (англиски)

Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Се регрутираФаза 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT05564390

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

Се регрутираФаза 1
  • OHSU Knight Cancer Institute, Portland
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT07548983

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Providence Willamette Falls Medical Center, Oregon City · на 12 милји
Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Се регрутираФаза 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Возраст од 18 до 59 · Сите полови · Ажурирано 28.9.2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Се регрутираФаза 3
  • Providence Portland Medical Center, Portland
  • Providence Oncology and Hematology Care Clinic Westside, Portland
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06852222

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Се регрутираФаза 1
  • OHSU Knight Cancer Institute, Portland
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT03874052

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Се регрутираФаза 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Возраст од 18 до 59 · Сите полови · Ажурирано 22.9.2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Се регрутираФаза 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Се регрутираФаза 3
  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
6 Months – 21 Years · Сите полови · Ажурирано 17.9.2026 · NCT04293562

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Се регрутираФаза 2
  • OHSU Knight Cancer Institute, Portland
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT06504459

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Се регрутираФаза 1/2
  • Oregon Health & Science University, Portland
30 Days · Сите полови · Ажурирано 16.9.2026 · NCT04065399

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Се регрутираФаза 1/2
  • Oregon Health and Science University, Portland
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT03471260

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Се регрутираФаза 3
  • US-Portland OR-OHSU, Portland
Возраст 18 и постари · Сите полови · Ажурирано 2.9.2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Се регрутираФаза 1/2
  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
До возраст 22 · Сите полови · Ажурирано 25.8.2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Се регрутираФаза 3
  • Doernbecher Children's Hospital, Portland
29 Days – 21 Years · Сите полови · Ажурирано 24.8.2026 · NCT05183035

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Се регрутираФаза 3
  • Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
Возраст од 18 до 75 · Сите полови · Ажурирано 17.7.2026 · NCT05429632

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Се регрутираФаза 1
  • OHSU Knight Cancer Institute, Portland
Возраст 18 и постари · Сите полови · Ажурирано 14.7.2026 · NCT04659616

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Се регрутираФаза 2
  • OHSU Knight Cancer Institute, Portland
Возраст од 18 до 65 · Сите полови · Ажурирано 13.7.2026 · NCT07228273

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Се регрутираФаза 2
  • Oregon Health and Science University, Portland
Возраст 18 и постари · Сите полови · Ажурирано 7.7.2026 · NCT07216443

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Се регрутираНабљудувачка студија
  • Oregon Health & Science University/Doernbecher Children's Hospital, Portland
Сите возрасти · Сите полови · Ажурирано 6.7.2026 · NCT01351545

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Се регрутираФаза 1
  • OHSU Knight Cancer Institute, Portland
Возраст 18 и постари · Сите полови · Ажурирано 30.6.2026 · NCT06357182

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Се регрутираФаза 2/3
  • Oregon Health and Science University, Portland
Возраст 18 и постари · Сите полови · Ажурирано 30.4.2026 · NCT04256317

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Се регрутираФаза 2
  • Oregon Health & Science University, Portland
Возраст од 18 до 66 · Сите полови · Ажурирано 17.3.2026 · NCT06859424

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Се регрутираФаза 1
  • OHSU, Portland
Возраст 18 и постари · Сите полови · Ажурирано 9.2.2026 · NCT06950034

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Се регрутираДобредојдени се здрави волонтери
  • Oregon Health & Science University, Portland
Возраст од 18 до 120 · Сите полови · Ажурирано 25.7.2025 · NCT05237258

Испитувања за Акутна миелоидна леукемија во други градови

Други студии во Portland

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.